The FDA approved GSK’s Jemperli (dostarlimab) in combination with carboplatin and paclitaxel for adults with primary advanced or recurrent endometrial cancer who are mismatch repair deficient or microsatellite instability-high.
Read the full post on Becker's Hospital Review - Healthcare News
